Nuvation Bio Inc (NUVB) Stock Price, Quote & News

Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 208 6102

Website: www.nuvationbio.com

Address:

1500 Broadway, Suite 1401, New York, United States

GMEryder Aug. 7 at 12:27 AM

$NUVB we could be trending tomorrow if david puts up a nice conference call

0 · Reply

imsofated Aug. 6 at 8:49 PM

$NUVB

0 · Reply

JanetBSmellin Aug. 6 at 8:24 PM

$NUVB Either goes back to $2.00 or up to $3.50. That’s my guess for the short term. GL bulls, and f*** cancer!

4 · Reply

1972Camaro Aug. 6 at 8:04 PM

$NUVB BIG DAY tomr, who knows what could happen🤑🤑🤑🤪

0 · Reply

Murfdog1968 Aug. 6 at 8:04 PM

$NUVB I saw it just jump to $2.41 for like 20 seconds.

0 · Reply

Murfdog1968 Aug. 6 at 8:03 PM

$NUVB it jumped the $2.41 for half a minute.

0 · Reply

GMEryder Aug. 6 at 7:59 PM

$NUVB what a comeback congrats to who held and bought the dip 💪🏻

0 · Reply

1972Camaro Aug. 6 at 7:42 PM

$NUVB this is about like a low float stock , nearly all shares locked up or shorted , could be a squeeze coming.

0 · Reply

JanetBSmellin Aug. 6 at 7:40 PM

$NUVB Another 1,000 at 2.26 for me. Gracias!

0 · Reply

imsofated Aug. 6 at 7:35 PM

$NUVB not if, but when

0 · Reply

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Jul 24, 2025, 4:05 PM EDT - 13 days ago

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 6 weeks ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Jun 16, 2025, 7:30 AM EDT - 7 weeks ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

Jun 11, 2025, 1:45 PM EDT - 2 months ago

US FDA approves Nuvation Bio's lung cancer therapy

Jun 11, 2025, 1:20 PM EDT - 2 months ago

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

May 21, 2025, 4:05 PM EDT - 2 months ago

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 13, 2025, 4:05 PM EDT - 3 months ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 12, 2025, 4:05 PM EDT - 3 months ago

Nuvation Bio to Participate in Upcoming Investor Conferences

May 11, 2025, 10:05 PM EDT - 3 months ago

Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 3 months ago

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 9:07 AM EDT - 3 months ago

Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes

May 1, 2025, 4:05 PM EDT - 3 months ago

Nuvation Bio to Present at The Citizens Life Sciences Conference

Apr 22, 2025, 4:05 PM EDT - 3 months ago

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Apr 2, 2025, 8:00 AM EDT - 4 months ago

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

Mar 25, 2025, 4:45 PM EDT - 4 months ago

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 8:00 AM EDT - 4 months ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Mar 6, 2025, 4:30 PM EST - 5 months ago

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:35 AM EST - 5 months ago

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Feb 24, 2025, 8:00 AM EST - 5 months ago

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 1:49 PM EST - 6 months ago

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

Feb 13, 2025, 5:09 PM EST - 6 months ago

Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst

Feb 3, 2025, 8:00 AM EST - 6 months ago

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 6, 2025, 4:05 PM EST - 7 months ago

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 7 months ago

Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 2, 2025, 7:00 PM EST - 7 months ago

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

Dec 23, 2024, 8:00 AM EST - 8 months ago

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

Dec 20, 2024, 7:10 AM EST - 8 months ago

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Nov 26, 2024, 8:00 AM EST - 9 months ago

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 4:05 PM EST - 9 months ago

Nuvation Bio to Present at the Jefferies London Healthcare Conference

Nov 11, 2024, 6:18 AM EST - 9 months ago

Top 4 Health Care Stocks That May Plunge This Quarter

AIRS PODD QDEL

Nov 6, 2024, 4:05 PM EST - 9 months ago

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 7, 2024, 4:05 PM EDT - 10 months ago

Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

Sep 14, 2024, 3:05 AM EDT - 11 months ago

Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Sep 9, 2024, 8:00 AM EDT - 11 months ago

Nuvation Bio to Present at the Cantor Global Healthcare Conference

Aug 8, 2024, 3:51 PM EDT - 1 year ago

Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib

Jun 2, 2024, 1:13 AM EDT - 1 year ago

Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

Jun 1, 2024, 8:00 PM EDT - 1 year ago

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

Jun 1, 2024, 8:10 AM EDT - 1 year ago

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

May 29, 2024, 4:05 PM EDT - 1 year ago

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 4:05 PM EDT - 1 year ago

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 10:01 AM EDT - 1 year ago

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 10, 2024, 4:01 PM EDT - 1 year ago

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Mar 31, 2024, 10:00 AM EDT - 1 year ago

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

Feb 29, 2024, 4:01 PM EST - 1 year ago

Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GMEryder Aug. 7 at 12:27 AM

$NUVB we could be trending tomorrow if david puts up a nice conference call

0 · Reply

imsofated Aug. 6 at 8:49 PM

$NUVB

0 · Reply

JanetBSmellin Aug. 6 at 8:24 PM

$NUVB Either goes back to $2.00 or up to $3.50. That’s my guess for the short term. GL bulls, and f*** cancer!

4 · Reply

1972Camaro Aug. 6 at 8:04 PM

$NUVB BIG DAY tomr, who knows what could happen🤑🤑🤑🤪

0 · Reply

Murfdog1968 Aug. 6 at 8:04 PM

$NUVB I saw it just jump to $2.41 for like 20 seconds.

0 · Reply

Murfdog1968 Aug. 6 at 8:03 PM

$NUVB it jumped the $2.41 for half a minute.

0 · Reply

GMEryder Aug. 6 at 7:59 PM

$NUVB what a comeback congrats to who held and bought the dip 💪🏻

0 · Reply

1972Camaro Aug. 6 at 7:42 PM

$NUVB this is about like a low float stock , nearly all shares locked up or shorted , could be a squeeze coming.

0 · Reply

JanetBSmellin Aug. 6 at 7:40 PM

$NUVB Another 1,000 at 2.26 for me. Gracias!

0 · Reply

imsofated Aug. 6 at 7:35 PM

$NUVB not if, but when

0 · Reply

1972Camaro Aug. 6 at 7:35 PM

$NUVB main man David holding 59million shares, if he's not scared I'm not either🤑🤑🤑

0 · Reply

GMEryder Aug. 6 at 7:34 PM

$NUVB nice rebound, tomorrow call at 8am 🔥

0 · Reply

1972Camaro Aug. 6 at 7:31 PM

$NUVB might b sorry but I'm holding thru 🫰🤑🤑🤑

0 · Reply

1972Camaro Aug. 6 at 7:29 PM

$NUVB looks like somebody's covering shorts now. Same as all week🤔🤔🤔

0 · Reply

Bio_Invest101 Aug. 6 at 7:28 PM

$NUVB https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-us-fda-approval-modeysotm/ Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma | Jazz Pharmaceuticals plc $DAWN

0 · Reply

Murfdog1968 Aug. 6 at 7:21 PM

$NUVB The old MacD indicator is looking like a bullish reversal!

0 · Reply

BioCapitalist99 Aug. 6 at 6:45 PM

$NUVB agree as well. Double bottom in place. A new leg up might be coming

0 · Reply

Willreid795 Aug. 6 at 6:38 PM

$NUVB iappears to be forming a double bottom around the $2.23-2.25 range. A great sign and pattern for upward action to follow, paired with earnings call and new updates on medication pipelines/guidance.

0 · Reply

Murfdog1968 Aug. 6 at 6:34 PM

$NUVB We're moving in the wrong direction again and I think tomorrow is going to be lackluster.

0 · Reply

TheWolf70 Aug. 6 at 6:09 PM

$NUVB not expecting really any Q2 sales numbers tomorrow since mid June approval and nearly every bio selling off after ER good or bad in this speculative market. Will get only anecdotal info on other launch execution metrics I think. Lightened position by half and will load back up if she dips significantly and hold remaining 50% regardless. Long term

1 · Reply

Samalex Aug. 6 at 5:50 PM

$NUVB 2Q25 earning report is scheduled to be released tomorrow 8/7/25 (premarket). Looking forward to hearing Ibtrozi sales numbers and licensing updates along with Safusidenibs progress report. Best of luck to all longs. NUVB share price is currently lower than pre-Ibtrozi FDA approval days.

1 · Reply

AdiDasRom Aug. 6 at 5:40 PM

$NUVB sorry bullish

0 · Reply

Market Cap	786.01M
Revenue (ttm)	7.87M
Net Income (ttm)	-567.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,216.52%
Debt to Equity Ratio	0.01

Volume	4,649,300
Avg Vol	6,545,960
Day's Range	N/A - N/A
Shares Out	340.26M
Stochastic %K	28%
Beta	1.35
Analysts	Strong Sell
Price Target	$7.17